MIRM
$96.55
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and ...
Recent News
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.
Mirum Completes Enrollment & Screening in Liver Disease Studies
MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Volatile Trading On Common Stock Offering News
Mirum Pharmaceuticals (MIRM) shares swung sharply after fourth quarter 2025 earnings, as investors weighed improved results against a sizable new common stock shelf registration that could eventually expand the share count meaningfully. See our latest analysis for Mirum Pharmaceuticals. Those mixed signals showed up in trading too, with a 1 day share price return of 0.11% and a 7 day share price return decline of 12.24%, while the 90 day share price return of 26.34% sits against a 1 year...
Mirum Pharmaceuticals Inc (MIRM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ...
Mirum Pharmaceuticals Inc (MIRM) reports a 55% increase in net product sales and outlines ambitious growth plans for 2026.